Stacey Goodman - Concepedia

Author

Stacey Goodman

Vanderbilt University Medical Center ORCID

Also Known As

Brian Engelhardt, S A Goodman, S Goodman, S. A. Goodman, S. Goodman, S.A. Goodman, Stacey A Goodman, Stacey A. Goodman, Stacey Ann Goodman, Stacey Goodman

117

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Vanderbilt University Medical Center Vanderbilt University The University of Texas MD Anderson Cancer Center Medical College of Wisconsin VA Tennessee Valley Healthcare System

About

Stacey Goodman is an author at Vanderbilt University Medical Center specializing in medicine, transplantation, and cell transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	1K
2	Health Sciences	6	6	443
3	Blood Transplantation	5	5	487
4	Natural Sciences	1	1	66
5	Allergy	1	1	24

Stacey Goodman

Publications

3.4K

Citations

H-Index

Page 1

	Year	Citations
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Robert H. Collins, Ofer Shpilberg, William R. Drobyski, Journal of Clinical Oncology	1997	1.3K
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis Efstathios Kastritis, Giovanni Palladini, Monique C. Minnema, New England Journal of Medicine	2021	609
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial Amrita Krishnan, Marcelo C. Pasquini, Brent R. Logan, The Lancet Oncology Hematological MalignancyCell TherapyTransplantationMarrow TransplantationStem Cell Transplantation	2011	277
The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro. Francis J. Hughes, J. Collyer, M Stanfield, Endocrinology SclerostinBone RepairOsteogenesisOsteoporosisOrthopaedic Surgery	1995	235
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma Robert F. Cornell, Bonnie Ky, Brendan M. Weiss, Journal of Clinical Oncology	2019	178
Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response Marcie Tomblyn, Marian Ewell, Christopher Bredeson, Biology of Blood and Marrow Transplantation Cell TherapyFirst Complete ResponseImmunologyMetronomic ChemotherapyImmunotherapy	2010	85
The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia Michael Byrne, Nathalie Danielson, Salyka Sengsayadeth, American Journal of Hematology Cell TherapyMixed-phenotype Acute LeukemiaImmunologyAllogeneic HctMyeloid Neoplasia	2020	78
Optimizing Antithymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Based on Recipient Absolute Lymphocyte Count Vanessa E. Kennedy, Heidi Chen, Bipin N. Savani, Biology of Blood and Marrow Transplantation	2017	69
Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers Salyka Sengsayadeth, Madan Jagasia, Barbara Engelhardt, Bone Marrow Transplantation Conventional MarkersOncogenic AgentMedicineGeneticsNatural Sciences	2012	66
Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator Eun‐jeong Kim, Benjamin Holmes, Shi Huang, EP Europace	2020	49

Page 1